Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case

Submitted: 31 December 2017
Accepted: 6 September 2018
Published: 9 July 2019
Abstract Views: 1129
PDF: 705
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Shobha, V., Desai, A., & Matthew, T. (2019). Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case. Reumatismo, 71(2), 99–102. https://doi.org/10.4081/reumatismo.2019.1115

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.